Team:UCL London

From 2010.igem.org

Revision as of 16:51, 27 October 2010 by Zcbee12 (Talk | contribs)

UCL IGEM 2010

RETURN TO IGEM 2010

  • Project Hypoxon aims to create cells capable of self-induction into the production phase, without the introduction of any chemical into the closed system.
    Project HYPOXON

  • We are an interdisciplinary group of students and advisers. Click on the The Team to find out more. Also watch our video to find out what an exciting and fulfilling summer we've had!
    iGEM Team

  • The construction of biological circuits was theoretically designed for more accurate prediction of its performance. Click to check out our project moedlling. Modeling

  • Want to read the detailed reports of all the amazing events that we've participated in and organized, then click on the link below.
    Public Engagements

  • We've had a great time using dozens of biobricks, check them out! BioBricks


  • Modeling

  • Want to know exactly what we've been doing on a daily basis and to find out how Project Hypoxon has progressed, visit our Notebook.
    Notebook

  • We would like to thank all our sponsors for their contribution and support throughout this summer project. To find out more about who did what, follow this link.
    Sponsors

Project Hypoxon

Click Animation UCL’s Biochemical engineering department has been at the forefront of biopharmaceutical manufacture for years. Extraordinary advances in the life sciences have great potential to improve our quality of life through better medicines and a cleaner environment. Our project aims to create “independent” cells, capable of self-induction into the production phase, without the introduction of any chemical into the closed system. By exploiting genetically modified E.coli to respond to hypoxia, we eliminate the need of IPTG induction. The functioning genetic circuit would be signalled by the production of a fluorescent green dye. While the green dye can be used as a live monitoring technique for oxygen, replacing the green dye gene with pharmaceutical protein promises higher yields and more consistent batches which is a step closer to providing cheaper healthcare to everyone.

Retrieved from "http://2010.igem.org/Team:UCL_London"